CCCC Q1 2022 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+3.1% YoY

Gross Profit

-$19M-242.3% margin

Operating Income

-$31M-409.8% margin

Net Income

-$32M-413.1% margin

EPS (Diluted)

$-0.65

QoQ Revenue Growth

-61.9%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$515M

Total Liabilities

$151M

Stockholders' Equity

$365M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$7M	+3.1%
Gross Profit	-$19M	-$13M	-41.6%
Operating Income	-$31M	-$41M	+23.6%
Net Income	-$32M	-$21M	-50.8%